Polynucleotide (Salmon DNA) Skin Boosters: An Evidence Check

What they are

What Polynucleotide Skin Boosters Actually Are

Polynucleotides are short fragments of purified DNA (typically from salmon or trout sperm or roe) suspended in an aqueous vehicle. They are injected superficially or intradermally into the dermis, most often on the face, neck, décolleté, and under-eyes.

They are not fillers in the volumizing sense. They produce minimal immediate plumping; the proposed effect is a slow, bioactive remodeling of skin quality over weeks.

The most-cited brand families are Plinest and Newest (Mastelli, Italy), Ameela (UK distribution), Rejuran (PDRN-based, Korea, distinct chemistry), and several emerging products.

Mechanism

Proposed Mechanism

Polynucleotides interact with adenosine A2A receptors and influence fibroblast activity. Published basic-science data show increased fibroblast proliferation, collagen and elastin synthesis, and modulation of inflammatory cytokines.

Clinically this is proposed to translate to improved skin hydration, reduced fine lines, brighter under-eyes, and improved skin elasticity over a treatment series (typically 3 sessions, 3–4 weeks apart, with annual touch-ups).

Evidence

What the Clinical Evidence Actually Shows

Published clinical data is dominated by small open-label series and a limited number of split-face randomized studies, mostly from Europe and Korea. Results suggest measurable improvement in skin hydration, elasticity (via cutometer), and patient-reported skin quality, particularly for under-eye and neck applications.

Effect sizes are modest. Polynucleotides are not a substitute for fillers in volume loss, lasers in pigmentation or texture, or microneedling-RF in laxity. They sit alongside these as a skin-quality adjunct.

Larger, longer-term randomized data is limited. Patients should be told: the mechanism is real, the early data is supportive, the long-term and head-to-head evidence is modest.

U.S. regulatory status

Regulatory Status in the United States

As of mid-2026, no polynucleotide skin booster is FDA-approved for aesthetic indications in the U.S.

Practices offering these injections are typically using imported product, compounded preparations, or off-label use of related compounds. Patients have the right to ask: what product is being used, how was it sourced, and what is its U.S. regulatory status?

By contrast, in the UK, EU, and most of Asia, several polynucleotide products are CE-marked and broadly available.

Where they fit

Where Polynucleotides Sensibly Fit in a Treatment Plan

• ·Skin quality and hydration in the late-20s to mid-40s patient who is not yet a candidate for volume restoration.
• ·Under-eye area in patients with thin, crepey skin where filler would be inappropriate.
• ·Neck and décolleté skin quality, where lasers and filler have limits.
• ·Adjunct to ablative or fractional laser recovery in selected patients.

They are not appropriate as a first-line treatment for volume loss, deep static rhytids, significant laxity, or pigmentation. Patients should expect modest, cumulative improvement — not a transformative single-treatment result.